329773-35-5
329773-35-5 結(jié)構(gòu)式
基本信息
4-[[(4-羧基丁基)[2-[2-[[4-(2-苯基乙基)苯基]甲氧基]苯基]乙基]氨基]甲基]苯甲酸
Cinaciguat
BAY 58-2667
Cinaciguat BAY-58-2667
4-[N-(4-Carboxybutyl)-N-[2-[2-[4-(2-phenylethyl)benzyloxy]phenyl]ethyl]aMinoMethyl]benzoic acid
4-[[(4-Carboxybutyl)[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]-benzoic acid
Benzoic acid, 4-[[(4-carboxybutyl)[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-14181R | CINACIGUAT Cinaciguat (Standard) | 329773-35-5 | 1 mg | 1100元 |
| 2026/06/05 | HY-14181R | CINACIGUAT Cinaciguat (Standard) | 329773-35-5 | 5 mg | 2200元 |
| 2026/06/05 | HY-14181R | CINACIGUAT Cinaciguat (Standard) | 329773-35-5 | 10 mg | 3300元 |
常見問題列表
Cinaciguat (10 μM) significantly enhances intracellular cGMP generation. Cinaciguat does not dose-dependent effects on cell contraction and calcium transients.
Cinaciguat (10 mg/kg/day, p.o.) treatment in diabetic rats does not influence blood glucose levels, but leads to attenuated water intake. Cinaciguat treatment alleviates diabetes mellitus related oxidative stress, protects against DM related alteration of the NO-sGC-cGMP-PKG signalling, and alleviates DM related myocardium hypertrophy and apoptosis. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not have any effect on phasic activity induced by PGF 2α in WT or apo-sGC strips.